ASKA PHARMACEUTICAL HOLDINGS CO.,LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,302 JPY | -1.67% |
|
+8.74% | +29.04% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company appears to be poorly valued given its net asset value.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +29.04% | 428M | - | ||
| +32.36% | 709B | C+ | ||
| +30.77% | 595B | B | ||
| -1.60% | 367B | C+ | ||
| +20.07% | 334B | B- | ||
| +6.04% | 289B | C+ | ||
| +14.77% | 239B | B+ | ||
| +9.13% | 211B | B- | ||
| -3.97% | 203B | A+ | ||
| +9.27% | 171B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4886 Stock
- Ratings ASKA Pharmaceutical Holdings Co.,Ltd.
